Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Hillard Rubin is active.

Publication


Featured researches published by Hillard Rubin.


Gene Therapy | 2009

Novel anti-VEGF chimeric molecules delivered by AAV vectors for inhibition of retinal neovascularization.

Peter Pechan; Hillard Rubin; Michael Lukason; J Ardinger; Elizabeth DuFresne; William W. Hauswirth; Samuel C. Wadsworth; Abraham Scaria

Vascular endothelial growth factor (VEGF) is important in pathological neovascularization, which is a key component of diseases such as the wet form of age-related macular degeneration, proliferative diabetic retinopathy and cancer. One of the most potent naturally occurring VEGF binders is VEGF receptor Flt-1. We have generated two novel chimeric VEGF-binding molecules, sFLT01 and sFLT02, which consist of the second immunoglobulin (IgG)-like domain of Flt-1 fused either to a human IgG1 Fc or solely to the CH3 domain of IgG1 Fc through a polyglycine linker 9Gly. In vitro analysis showed that these novel molecules are high-affinity VEGF binders. We have demonstrated that adeno-associated virus serotype 2 (AAV2)-mediated intravitreal gene delivery of sFLT01 efficiently inhibits angiogenesis in the mouse oxygen-induced retinopathy model. There were no histological observations of toxicity upon persistent ocular expression of sFLT01 for up to 12 months following intravitreal AAV2-based delivery in the rodent eye. Our data suggest that AAV2-mediated intravitreal gene delivery of our novel molecules may be a safe and effective treatment for retinal neovascularization.


Molecular Therapy | 2011

Inhibition of choroidal neovascularization in a nonhuman primate model by intravitreal administration of an AAV2 vector expressing a novel anti-VEGF molecule.

Michael Lukason; Elizabeth DuFresne; Hillard Rubin; Peter Pechan; Qiuhong Li; Ivana K. Kim; Szilard Kiss; Christina J. Flaxel; Margaret E Collins; Joan W. Miller; William W. Hauswirth; Timothy K. MacLachlan; Samuel C. Wadsworth; Abraham Scaria

Inhibition of vascular endothelial growth factor (VEGF) for the management of the pathological ocular neovascularization associated with diseases such as neovascular age-related macular degeneration is a proven paradigm; however, monthly intravitreal injections are required for optimal treatment. We have previously shown that a novel, secreted anti-VEGF molecule sFLT01 delivered by intravitreal injection of an AAV2 vector (AAV2-sFLT01) gives persistent expression and is efficacious in a murine model of retinal neovascularization. In the present study, we investigate transduction and efficacy of an intravitreally administered AAV2-sFLT01 in a nonhuman primate (NHP) model of choroidal neovascularization (CNV). A dose-dependent and persistent expression of sFLT01 was observed by collecting samples of aqueous humor at different time points over 5 months. The location of transduction as elucidated by in situ hybridization was in the transitional epithelial cells of the pars plana and in retinal ganglion cells. AAV2-sFLT01 was able to effectively inhibit laser-induced CNV in a dose-dependent manner as determined by comparing the number of leaking CNV lesions in the treated versus control eyes using fluorescein angiography. Our data suggest that intravitreal delivery of AAV2-sFLT01 may be an effective long-term treatment for diseases caused by ocular neovascularization.


Molecular therapy. Methods & clinical development | 2014

Aurintricarboxylic acid increases yield of HSV-1 vectors

Peter Pechan; Jeffery Ardinger; Jyothi Ketavarapu; Hillard Rubin; Samuel C. Wadsworth; Abraham Scaria

Production of large quantities of viral vectors is crucial for the success of gene therapy in the clinic. There is a need for higher titers of herpes simplex virus-1 (HSV-1) vectors both for therapeutic use as well as in the manufacturing of clinical grade adeno-associated virus (AAV) vectors. HSV-1 yield increased when primary human fibroblasts were treated with anti-inflammatory drugs like dexamethasone or valproic acid. In our search for compounds that would increase HSV-1 yield, we investigated another anti-inflammatory compound, aurintricarboxylic acid (ATA). Although ATA has been previously shown to have antiviral effects, we find that low (micromolar) concentrations of ATA increased HSV-1 vector production yields. Our results showing the use of ATA to increase HSV-1 titers have important implications for the production of certain HSV-1 vectors as well as recombinant AAV vectors.


Archive | 2014

Fusion proteins comprising pdgf and vegf binding portions and methods of using thereof

Peter Pechan; Jeffery Ardinger; Hillard Rubin; Samuel C. Wadsworth; Abraham Scaria


Molecular Therapy | 2004

523. Inhibition of retinal neovascularization by intraocular gene delivery of soluble VEGF receptors

Abraham Scaria; Peter Pechan; Michael Lukason; Hillard Rubin; Samuel C. Wadsworth


Investigative Ophthalmology & Visual Science | 2015

Role of Myocilin Mutants and Wnt Signaling in Glaucoma

Peter Pechan; Jeffery Ardinger; Hillard Rubin; Michael Lukason; Elizabeth Barry; Seng Cheng; Abraham Scaria


Archive | 2014

PROTEÍNAS DE FUSIÓN COMPRENDIENDO PORCIONES PDGF y VEGF DE UNIÓN Y MÉTODOS PARA SU USO

Peter Pechan; Jeffery Ardinger; Hillard Rubin; Samuel C. Wadsworth; Abraham Scaria


Cancer Research | 2009

Abstract #4090: In vitro and in vivo evaluation of novel VEGF-binding proteins, sFLT01 and sFLT02

Rebecca G. Bagley; Min Yao; Leslie Kurtzberg; William Weber; Hillard Rubin; Kerry Culm-Merdek; Christine Burnett; Lucy Yen; Elizabeth Isenberger; Cindy Rogers; Cecile Rouleau; Peter Pechan; William Brondyk; Abraham Scaria; Johanne Kaplan; Beverly A. Teicher


Investigative Ophthalmology & Visual Science | 2008

Minimal Effective Dosing of a Novel Recombinant Form of VEGF Soluble Receptor 1 (sFlt-1) Delivered via AAV Vector in Inhibiting Choroidal Neovascularization in a Murine Model

William W. Hauswirth; R. Miller; Ji-jing Pang; V. Choido; A. Abraham; Peter Pechan; Hillard Rubin; Samuel C. Wadsworth; Q. Li


Molecular Therapy | 2006

883. AAV-2 Based Gene Therapy Using Novel Anti-VEGF Molecules for Inhibition of Angiogenesis in the Eye

Abraham Scaria; Peter Pechan; Hillard Rubin; Michael Lukason; Elizabeth Barry; Jeffrey Ardinger; Huawei Qiu; Qiuhong Li; James J. Peterson; William W. Hauswirth; Samuel C. Wadsworth

Collaboration


Dive into the Hillard Rubin's collaboration.

Researchain Logo
Decentralizing Knowledge